纤维肌痛药物市场规模、份额及成长分析（依药物类别、诊断方法、给药途径、药物类型、治疗通路、通路、最终用户及地区）－2025-2032 年产业预测

2023 年全球纤维肌痛药物市场规模价值 35 亿美元，预计将从 2024 年的 37.9 亿美元成长到 2032 年的 71.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.2%。

纤维肌痛症是一种慢性疼痛疾病，影响全球约 2% 的成年人，表现为广泛的疼痛、疲劳以及睡眠障碍和认知障碍等其他症状，女性的盛行率明显更高。虽然没有治疗方法，但有各种治疗策略来改善症状管理并提高患者的生活品质。这些治疗策略整合了药物治疗、生活方式改变和非药物治疗，旨在缓解疼痛、改善睡眠品质和解决认知问题。纤维肌痛的复杂性需要采用多学科治疗方法，通常根据每个人的独特需求进行定制，突出了个人化治疗对于有效管理这种多方面疾病的重要性。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局

纤维肌痛治疗市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概览
• 抗忧郁症
• 抗惊厥药
• 肌肉鬆弛剂
• 其他的

纤维肌痛治疗市场规模（依诊断方法及复合年增长率）（2025-2032）

• 市场概览
• 血液检查
• 身体检查

纤维肌痛治疗市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概览
• 口服
• 注射剂
• 局部的

纤维肌痛治疗药物市场规模（依药物类型及复合年增长率）（2025-2032）

• 市场概览
• 品牌
• 非专利的

纤维肌痛治疗市场规模（依治疗管道及复合年增长率） (2025-2032)

• 市场概览
• 医院
• 诊所
• 居家照护

纤维肌痛治疗药物市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局

纤维肌痛治疗药物市场规模（按最终用户和复合年增长率划分）（2025-2032）

• 市场概览
• 成人
• 孩子们

纤维肌痛治疗药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GlaxoSmithKline plc（UK）
• Aptinyx Inc.（USA）
• Tonix Pharmaceuticals Holding Corp.（USA）
• Virios Therapeutics（USA）
• Astellas Pharma Inc.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Boehringer Ingelheim GmbH（Germany）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• Merck & Co., Inc.（USA）
• Bristol-Myers Squibb Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Mylan NV（USA）
• Lupin Limited（India）

结论和建议

Global Fibromyalgia Treatment Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.79 billion in 2024 to USD 7.11 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

Fibromyalgia, a chronic pain disorder that affects approximately 2% of adults globally, manifests through widespread pain, fatigue, and additional symptoms like sleep disturbances and cognitive difficulties, with a notably higher prevalence in women. Although there is no cure, various treatment strategies exist to improve symptom management and enhance the quality of life for those affected. These strategies integrate medications, lifestyle changes, and non-pharmacological therapies, aiming to alleviate pain, improve sleep quality, and tackle cognitive issues. The complexity of fibromyalgia necessitates a multidisciplinary treatment approach, often customized to meet the unique needs of each individual, highlighting the importance of personalized care in effectively managing this multifaceted condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fibromyalgia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Fibromyalgia Treatment Market Segments Analysis

Global Fibromyalgia Treatment Market is segmented by Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User and region. Based on Drug Class, the market is segmented into Antidepressants, Antiepileptics, Muscle Relaxants and Others. Based on Diagnosis Method, the market is segmented into Blood Tests and Physical Examination. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Drug Type, the market is segmented into Branded and Generic. Based on Treatment Channel, the market is segmented into Hospitals, Clinics and Homecare. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End User, the market is segmented into Adults and Pediatrics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Fibromyalgia Treatment Market

The global fibromyalgia treatment market is primarily driven by the rising incidence of fibromyalgia across the globe. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates that around five million adults in the United States are affected by this condition, with a staggering 80 to 90 percent of patients being women. This gender disparity highlights the significant toll fibromyalgia takes on women. As awareness surrounding the condition grows and diagnostic methods advance, more cases are being identified globally. Additionally, the limited number of specifically approved medications, currently just three, has led to increased dependence on off-label and generic treatments, further influencing market dynamics. The expiration of patent protections for Lyrica in June 2019 has also introduced generic alternatives, intensifying competition and impacting overall market growth.

Restraints in the Global Fibromyalgia Treatment Market

The Global Fibromyalgia Treatment market faces notable restraints due to the limited number of drugs specifically approved for this condition, currently standing at only three options. This scarcity leads to a greater reliance on off-label medications and generic antidepressants to manage symptoms. Moreover, the expiration of patent protection for Lyrica, a crucial medication for fibromyalgia treatment, in June 2019 has significantly impacted market revenues. The introduction of generic alternatives has intensified competition, which further constrains overall market growth. These factors collectively hinder advancements and limit treatment options available to individuals suffering from fibromyalgia worldwide.

Market Trends of the Global Fibromyalgia Treatment Market

The Global Fibromyalgia Treatment market is witnessing a notable trend toward the introduction of innovative therapies, driven by key industry players aiming to enhance their presence. The anticipated launch and approval of novel treatments, such as Galcanezumab by Eli Lilly and Company, highlights a strategic focus on expanding existing drug indications to better address the multifaceted needs of fibromyalgia patients. With Galcanezumab currently undergoing clinical trials for fibromyalgia, its upcoming results may significantly impact market dynamics. This proactive engagement in research and development underscores a growing commitment within the pharmaceutical sector to develop effective solutions, thereby contributing to robust market growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Fibromyalgia Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antidepressants
• Antiepileptics
• Muscle Relaxants
• Others

Global Fibromyalgia Treatment Market Size by Diagnosis Method & CAGR (2025-2032)

• Market Overview
• Blood Tests
• Physical Examination

Global Fibromyalgia Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical

Global Fibromyalgia Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generic

Global Fibromyalgia Treatment Market Size by Treatment Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare

Global Fibromyalgia Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Fibromyalgia Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Adults
• Pediatrics

Global Fibromyalgia Treatment Market Size & CAGR (2025-2032)

• North America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptinyx Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonix Pharmaceuticals Holding Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations